Siemens Corporate Research spin-off and Speedus Corp. subsidiary, Zargis Medical Corp., announced Friday that it has received U.S. Food and Drug Administration clearance to market the new Signal X6(TM) device. The company also announced that seven Signal X6 devices have been delivered to the U.S. Army for deployment in six Department of Defense medical facilities.

Signal X6 technology records heart and lung sounds from six adhesive sensors. The recordings can be evaluated locally or, when a cardiac specialist is not immediately available, transmitted through the Internet for remote evaluation. This feature makes the noninvasive technology easy to use. The configuration of the Signal X6 provides a unique telemedicine resource in situations where evaluations could benefit from high fidelity multi-channel synchronous recordings.

Prototypes for Signal X6 were first developed with funding from the Telemedicine and Advanced Technology Research Center (TATRC), of the USAMRMC, through the AAMTI program. The AAMTI program provides funding to

Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE:SI), a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), develops diagnostic decision support products and services for healthcare professionals. The company today announced that it has begun selling its Zargis Cardioscan heart sound analysis software, as well as 3M Health Care’s (NYSE: MMM) recently launched Bluetooth-enabled 3M Littmann Electronic Stethoscope Model 3200.

The introduction of the products into the marketplace is part of Zargis’ existing multi-year global marketing deal with 3M, which equips Zargis with extended marketing and promotional opportunities, as well as worldwide distribution rights of its products through 3M’s Littmann brand.

Zargis’ Cardioscan software provides support to physicians, analyzing and interpreting cardiac sounds, which gives them an upper hand in dealing with possible heart disease. Cardioscan is wirelessly connected to 3M’s Littmann Electronic Stethoscope Model 3200, which allows users to easily share and compare heart sounds recordings and related comments

Speedus Corp. announced today that it has promoted John Kallassy to chief financial officer. Mr. Kallassy has served as executive vice president of Speedus for approximately eight years and will continue to serve as chief executive officer for Zargis Medical Corp., a position he has held for the past 4 years. Zargis is a majority-owned subsidiary of Speedus.

“John has done an outstanding job as Zargis’ CEO, where he successfully led the company from its research and development stage to a comprehensive product launch through a global marketing alliance with 3M,” commented Shant Hovnanian, Speedus’ chairman and CEO. “John’s enthusiasm is contagious and he has certainly earned this promotion and expanded role.”

Prior to his current leadership positions, John was a founder and the CEO of American Data Consultants (ADC). In 1997, Mr. Kallassy sold ADC to R.L. Polk and was employed with R.L. Polk for three years as the ADC division